Characterization of spontaneous osteogenesis after surgical segmental bone defect in a large animal
Ended Awarded Last action
- Contract number
- 75N95023F00001
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $385,704
Award facts
- Opportunity
-
- 75N95023R00045 Solicitation number
- Contract value 100% obligated
- $385,704.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $192,050 | |
| Original award | $193,654 |
About this award
This is a $385,704.00 cost-plus-fixed-fee delivery order contract awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to the Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract is for the characterization of spontaneous osteogenesis, or bone formation, after surgical segmental bone defect in a large animal model. The work will take place in Albuquerque, New Mexico. Lovelace Biomedical Research Institute has a broad range of experience conducting animal studies, including for federal agencies like the NIH, Department of Defense, and HHS, to support drug and product development across areas like infectious diseases, gene therapies, and medical countermeasures. The contract does not have a set-aside designation.
Quick answers
Who was awarded contract 75N95023F00001?
75N95023F00001 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on August 7, 2023.
How much is contract 75N95023F00001 worth?
The government has obligated $385,704 on 75N95023F00001.
Which agency awarded contract 75N95023F00001?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95023F00001, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95023F00001 an order under another contract?
Yes. 75N95023F00001 is a delivery order under 75N95019D00012, an indefinite delivery contract.
Was contract 75N95023F00001 competed?
The extent of competition for 75N95023F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award